A Case for Reframing ‘Skin of Color’ - Scorecard - MDSpire

A Case for Reframing ‘Skin of Color’

The term that transformed dermatology is now blurring the very distinctions it was meant to sharpen.

  • By

  • Kerri Miller

  • March 20, 2026

  • 2 min

Share

Clinical Scorecard: A Case for Reframing ‘Skin of Color’

At a Glance

CategoryDetail
ConditionSkin of Color (SOC)
Key MechanismsVariability in melanin distribution, UV sensitivity, pigmentary genetics, and treatment response.
Target PopulationPatients with darker skin types, particularly Fitzpatrick types V and VI.
Care SettingDermatology clinics and research contexts.

Key Highlights

  • The Fitzpatrick scale inadequately represents darker skin types.
  • SOC has evolved to encompass equity in education and research.
  • SOC can obscure clinically meaningful differences among patients.
  • A granular approach to SOC is proposed, focusing on specific components.
  • Tools for measuring pigment phenotype are underused in clinical practice.

Guideline-Based Recommendations

Diagnosis

  • Clarify which SOC dimension is relevant in clinical contexts.

Management

  • Utilize tools like ITA, Melanin Index, or Monk Skin Tone for assessing pigment phenotype.

Monitoring & Follow-up

  • Consider pigment-linked clinical risk modifiers in treatment plans.

Risks

  • Be aware of postinflammatory hyperpigmentation and keloid tendency in SOC patients.

Patient & Prescribing Data

Individuals with Fitzpatrick types V and VI.

Individualized care is essential, considering specific pigment and sociocultural factors.

Clinical Best Practices

  • Integrate training on SOC components into dermatology practice.
  • Encourage institutional endorsement for the use of measurement tools.

Related Resources & Content

Original Source(s)

A Case for Reframing ‘Skin of Color’

  • by Kerri Miller

  • March 20, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.